Wall Street analysts forecast that Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) will announce sales of $1.75 million for the current quarter, Zacks reports. Three analysts have provided estimates for Dicerna Pharmaceuticals’ earnings. The highest sales estimate is $1.88 million and the lowest is $1.67 million. Dicerna Pharmaceuticals posted sales of $130,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 1,246.2%. The firm is expected to announce its next quarterly earnings report on Monday, May 14th.
According to Zacks, analysts expect that Dicerna Pharmaceuticals will report full year sales of $1.75 million for the current financial year, with estimates ranging from $6.50 million to $8.30 million. For the next financial year, analysts expect that the business will post sales of $12.13 million per share, with estimates ranging from $2.94 million to $26.68 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Dicerna Pharmaceuticals.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.25). The company had revenue of $1.40 million for the quarter, compared to analysts’ expectations of $1.45 million. Dicerna Pharmaceuticals had a negative return on equity of 171.81% and a negative net margin of 2,637.15%. The business’s revenue was up 976.9% on a year-over-year basis.
Hedge funds have recently added to or reduced their stakes in the stock. Northern Trust Corp raised its position in Dicerna Pharmaceuticals by 6.1% in the 2nd quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 2,094 shares during the last quarter. Endurant Capital Management LP purchased a new stake in Dicerna Pharmaceuticals in the 4th quarter valued at $170,000. Emerald Advisers Inc. PA purchased a new stake in Dicerna Pharmaceuticals in the 4th quarter valued at $266,000. EAM Investors LLC purchased a new stake in Dicerna Pharmaceuticals in the 4th quarter valued at $581,000. Finally, Millennium Management LLC raised its position in Dicerna Pharmaceuticals by 142.8% in the 4th quarter. Millennium Management LLC now owns 66,907 shares of the biopharmaceutical company’s stock valued at $604,000 after purchasing an additional 39,348 shares during the last quarter. Hedge funds and other institutional investors own 75.28% of the company’s stock.
Shares of NASDAQ:DRNA traded down $0.25 during trading on Friday, hitting $9.44. 251,734 shares of the company were exchanged, compared to its average volume of 445,731. The company has a market capitalization of $495.93, a PE ratio of -2.58 and a beta of 2.34. Dicerna Pharmaceuticals has a 12-month low of $2.69 and a 12-month high of $15.00.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.